CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of two peer-reviewed papers documenting systemic delivery of RNAi therapeutics to certain immune and inflammatory cells. These studies provide a foundation for the potential development of RNAi therapeutics to silence disease genes in these cell types for the treatment of inflammatory, autoimmune, and cardiovascular diseases, as well as certain cancers.
